Headache after Intrathecal Catheter - Subcutaneous Access Port Insertion for Cancer Pain Treatment – Case Report

Approximately 5-15% of cancer patients experience severe pain (6-10 based on VAS) that is resistant to traditional analgesic therapies. For this patient selective interventional analgesic treatment, options must be considered. The Polyanalgesic Consensus Conference panel of experts made the recommendations on use of intrathecal analgesics based on preclinical trials and clinical experiences. On the other hand, intrathecal drug delivery by the implantable pump or subcutaneous port-catheter can be complicated with PDPH. In these cases, EBP is needed if conservative treatment failed.